Clinical trial aimed at a complete cure of HAM by prosultiamine treatment with oral administration

Clinical trial aimed at a complete cure of HAM by prosultiamine treatment with oral administration - Oral prosultiamine treatment against HAM patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004478

Enrollment

Registered

2010-11-01

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HTLV-I associated myelopathy (HAM)

Interventions

Oral administration of prosultiamine at dosages of 300mg daily for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HAM patients who fulfilled the criteria of WHO

Exclusion criteria

Exclusion criteria: HAM patients who do not approve the protocol

Design outcomes

Primary

Measure	Time frame
The improvement of neurological signs including motor disability score and the decrease of HTLV-I-infected cells in the peripheral blood at 4 weeks after commencement.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026